Trial Profile

A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies After Progression on Prior PD-1 Inhibitor Treatment

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brentuximab vedotin (Primary) ; Pembrolizumab (Primary)
Indications Carcinoma; Malignant melanoma; Non-small cell lung cancer; Skin cancer; Squamous cell cancer
Focus Therapeutic Use
Sponsors Seagen

Most Recent Events

13 May 2025 Planned number of patients changed from 142 to 141.
18 Apr 2025 Planned End Date changed from 30 Sep 2026 to 31 Dec 2029.
18 Apr 2025 Planned primary completion date changed from 31 Dec 2025 to 31 Dec 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com